Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FDA inspectors last year noted issues at a manufacturing site now being used to produce the monoclonal antibody LY-CoV555.

Eli Lilly's COVID-19 Treatment Candidate Has a Manufacturing Site Problem

The National Institutes of Health put the brakes on the study in what the drugmaker calls "an abundance of caution."

Eli Lilly Coronavirus Antibody Drug Trial Paused

Eli Lilly (LLY) shareholders are hitting the exits after reports raised questions about the company's COVID-19 candidate.

Eli Lilly (LLY) Selling Off After Safety Disclosures

Lilly (LLY) is developing antibody candidates for a potential COVID-19 treatment in several clinical studies.

Lilly's Coronavirus Antibody Study Paused on Safety Concerns

The feds found serious quality-control lapses at a New Jersey factory where Eli Lilly & Co. plans to produce its antibody treatment for COVID-19, a new report says. Food and Drug Administration officials who spent 10 days inspecting the drugmaker’s Branchburg plant last November discovered that data on the facility’s manufacturing processes had been deleted.

FDA reportedly found quality-control lapses at Eli Lilly plant making COVID-19 drug

Shares of Eli Lilly & Co. were down 0.5% in premarket trading on Wednesday, the day after the drug maker confirmed that a clinical trial for its COVID-19 antibody treatment in combination with remdesivir had been paused. Gilead Sciences Inc. received emergency authorization for remdesivir in May as a COVID-19 therapeutic.

NIH confirms trial for Lilly antibody treatment is paused

There's more good news than bad for the big drugmaker.

Late-Stage Study of Lilly's COVID-19 Antibody Therapy Paused: Buy the Stock on the Dip?

The Eli Lilly And Co (NYSE: LLY) plant being readied to make an antibody therapy for COVID-19 has been found to have serious quality control problems by the United States Food and Drug Administration, Reuters reported Tuesday. What Happened: As per government documents, two inspectors who visited the drugmaker’s Branchburg, New Jersey plant last November, found that data on various manufacturing processes had been deleted and not audited properly.

Eli Lily COVID-19 Antibody Therapy Plant Has Serious Quality Control Issues, FDA Finds: Report

Johnson & Johnson

"It's kind of paradoxical, but actually it's reassuring" to see coronavirus drug trials paused when safety concerns arise, former CDC Director Dr. Tom Frieden told CNBC.

Ex-CDC director: Pauses to coronavirus drug trials give 'reassurance' that corners aren't being cut

In the race to get COVID-19 treatment options to market, Eli Lilly is the latest to suffer a setback. What Happened: The New York Times reports Eli Lilly and Co (NYSE: LLY) paused its Phase 3 clinical trial for the ACTIV-3 antibody treatment.

Eli Lilly Halts Antibody COVID-19 Trial

President Trump has promoted the company’s antibody treatment in recent videos.

Eli Lilly Covid-19 Antibody Treatment Trial Is Paused Due To 'Potential Safety Concern'

Eli Lilly (LLY) on Tuesday confirmed it's halted final-stage testing of its Covid-19 treatment candidate on potential safety concerns by U.S. health regulators, and LLY stock fell.

Eli Lilly Pauses Covid-19 Treatment Clinical Trials Over Safety Concerns

Shares of Eli Lilly & Co. tumbled 3.1% in trading on Tuesday after the drug maker confirmed a data safety monitoring board had paused enrollment in a clinical study testing its experimental COVID-19 monoclonal antibody treatment in combination with Gilead Sciences Inc.'s remdesivir. "Safety is of the utmost importance," a company spokesperson said in an email.

A study testing Lilly's antibody treatment and remdesivir is paused

U.S. drugmaker Eli Lilly and Co said on Tuesday that the government-sponsored clinical trial of its COVID-19 antibody treatment has been paused because of a safety concern.

Eli Lilly antibody trial paused due to potential safety concern

The ACTIV-3 monoclonal antibody trial - a phase three randomized controlled trial - has been paused due to potential safety concerns, Eli Lilly confirmed to CNBC.

U.S. pauses Eli Lilly's trial of a coronavirus antibody treatment over safety concerns

Eli Lilly's (LLY) mirikizumab continues to show symptom improvement and reduction of intestinal mucosal inflammation in Crohn's disease patients after a year-long treatment in a mid-stage study.

Lilly's Mirikizumab Retains Efficacy in Crohn's Disease Study

Apple

Alibaba

Canopy Growth

Cigna

UnitedHealth Group

Walgreens

Investors have these seven election stocks to consider avoiding, as uncertainties grow in the near-term and market selling rises. The post 7 Elections Stocks You Definitely Want To Avoid Leading up To the Big Vote appeared first on InvestorPlace.

7 Elections Stocks You Definitely Want To Avoid Leading up To the Big Vote

Regeneron Pharmaceuticals

Here's why Americans could soon have access to treatments that prevent mild infections from becoming severe.

Effective Antibody Treatments for COVID-19 Could Be Ready Soon

SAN FRANCISCO and SUZHOU, China, Oct. 9, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major...

Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China

INDIANAPOLIS, Oct. 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2020 financial results on Tuesday, October 27, 2020. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's...

Lilly Confirms Date and Conference Call for Third-Quarter 2020 Financial Results Announcement

Incyte

INDIANAPOLIS, Oct. 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) are sharing additional data showing baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with...

Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen

Lilly (LLY) applies to the FDA for Emergency Use Authorization of antibody therapy, LYCoV555. Releases promising data which shows that an antibody combination, LYCoV555 and LY-CoV016, is effective.

Lilly Seeks Emergency Use of Coronavirus Antibody Candidate

INDIANAPOLIS, Oct. 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and the Bill & Melinda Gates Foundation, as part of the COVID-19 Therapeutics Accelerator, have entered into an agreement to facilitate access to future Lilly therapeutic antibodies under development for the...

Lilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries

The antibody treatment helps reduce the rate of hospitalization for Covid-19 patients.

Eli Lilly Seeks Emergency Authorization For Covid-19 Drug, May Produce 100,000 Doses By Month-End

Drugmaker Eli Lilly says it has asked the US government to allow emergency use of its experimental antibody therapy based on early results from a study that suggested the drug reduced symptoms, the amount of virus, hospitalizations and ER visits for patients with mild or moderate COVID-19. Eli Lilly announced the partial results Wednesday in.

News for Eli Lilly Stock (LLY)